Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.160 +0.270 (+6.94%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
News headline image
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex ↗
A number of financial firms and investment banks 
Via Benzinga
News headline image
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings ↗
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: 
Via Benzinga
News headline image
Palo Santo: New Venture Capital Group Raises $35M To Focus On Psychedelic Medicine ↗
Palo Santo, a newly-created venture capital fund with an eye on psychedelic medicines, announced its official launch on Thursday. 
Via Benzinga
News headline image
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks ↗
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing... 
Via Talk Markets
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021 ↗
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 ↗
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
News headline image
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
News headline image
The 6 Leading Psychedelic Stocks In Drug R&D ↗
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 ↗
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
News headline image
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech ↗
It's off to a running start. 
Via The Motley Fool
News headline image
Atai IPO Day An Underwhelming Event ↗
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform ↗
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
News headline image
58 Biggest Movers From Friday ↗
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
News headline image
Opening Day: WalkMe Stock Price Falls Following $287M IPO ↗
Backed by Insight Venture Partners, WalkMe fell as much as 7% in its trading debut earlier this week after a $287M initial public offering. According to filings, Insight will remain WalkMe's biggest... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public ↗
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
News headline image
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End ↗
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Is ATAI Stock A Buy After The IPO? ↗
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. 
Via Talk Markets
News headline image
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings ↗
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
News headline image
Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation ↗
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offer... 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.